The Institute of Pharmaceutical Innovation

Tuesday 28th April, 2009 IPI launches fundraising campaign to make better HIV medicines for children

The IPI along with its global partners is committed to developing child friendly improved HIV medicines.

We are looking to raise funds from generous individuals in order to help our cause.

To find out more about the project please click here

Read more of "IPI launches fundraising campaign to make better HIV medicines for children"...

Wednesday 15th April, 2009 Syntopix sign exclusive evaluation agreement

Syntopix Group based in the IPI incubator has signed an exclusive evaluation agreement with a major consumer healthcare company.

Syntopix Group plc (AIM: SYN), the speciality pharmaceutical research and development company focused on topical treatment of dermatological diseases, is pleased to announce that it has signed an exclusive evaluation agreement with a major consumer healthcare company. In this agreement, Syntopix will make available the Company’s library of compounds for evaluation of their application in a number of areas as candidates for development into commercial products.

Read more of "Syntopix sign exclusive evaluation agreement"...

Wednesday 15th April, 2009 85% of IPI Research of International Quality

The recent 2008 Research Assessment Exercise (RAE) in the UK has confirmed the research strengths of the Institute of Pharmaceutical Innovation. Assessing the quality of publications and other outputs, the research environment and esteem, 85% of research in the IPI was judged to be of international standard and above. More than half of all research in the IPI was judged to be internationally excellent or world-leading.

Commenting on the performance of the IPI in the 2008 RAE , the Institute’s Principal Scientist Professor Peter York said: “This is a strong performance by the IPI team, and shows we are making great progress in our science and innovation activities. The RAE 2008 results reflect outstanding research strengths in the Institute, in predictive pharmaceutics, analytics and drug delivery. It is pleasing too to see recognition of many of the activities which make the IPI an innovation institute, committed through its partners and contacts with industry to translating strong science into better medicines for the benefit of patients world-wide.”

Read more of "85% of IPI Research of International Quality"...